Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 4/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 10/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.39 |
| ▸ | MELK | Q14680 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21747865 | 1.00 | BTK (0.40) | BTKJAK3FGFR4ERBB2ALK | |
| SCHEMBL30090107 | 0.96 | BTK (0.41) | BTKERBB2ALKMELKPARP1 | |
| SCHEMBL21747847 | 0.96 | BTK (0.41) | BTKERBB2ALKMELKPARP1 | |
| SCHEMBL21747876 | 0.93 | BTK (0.42) | BTKJAK3FGFR4ERBB2ALK | |
| SCHEMBL30090217 | 0.93 | BTK (0.42) | BTKJAK3FGFR4ERBB2ALK | |
| SCHEMBL21747955 | 0.85 | BTK (0.43) | BTKJAK3FGFR4ERBB2EGFR | |
| SCHEMBL30090187 | 0.85 | BTK (0.43) | BTKJAK3FGFR4ERBB2EGFR | |
| SCHEMBL21747886 | 0.84 | FGFR4 (0.42) | BTKJAK3FGFR4ERBB2ALK | |
| SCHEMBL30090147 | 0.84 | FGFR4 (0.42) | BTKJAK3FGFR4ERBB2ALK | |
| SCHEMBL21747846 | 0.84 | ERBB2 (0.49) | BTKJAK3FGFR4ERBB2ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220370440-A1 | 4-SUBSTITUTED PYRROLO[2,3-B]PYRIDINE AS ERBB MODULATORS USEFUL FOR TREATING CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2022-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220370440-A1 | 4-SUBSTITUTED PYRROLO[2,3-B]PYRIDINE AS ERBB MODULATORS USEFUL FOR TREATING CANCER | ERBB2, ERBB4, ERBB3 | BTK 148/4885JAK3 188/4885FGFR4 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.